Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Mondelez International logoMondelez International MDLZ

The company said it increased the size of its Board of Directors from 10 to 11 members on February 1, 2024 and appointed Brian J. McNamara to the Board, effective February 1, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary

  1. The company said it increased the size of its Board of Directors from 10 to 11 members on February 1, 2024 and appointed Brian J. McNamara to the Board, effective February 1, 2024.

  2. The company said McNamara has been Chief Executive Officer of Haleon plc (formerly GSK ConsumerHealthcare) since May 2022, and previously led GSK's Consumer Healthcare business.

  3. The company said it appointed McNamara to the People and Compensation Committee and the Governance, Membership and Sustainability Committee, and that the Board determined he is an independent director under Nasdaq listing rules. According to the press release, 10 of the 11 directors, including McNamara, are deemed independent.

  4. The company said McNamara will receive the same compensation and indemnification as its other non-employee directors, that there are no transactions between him and the company reportable under Item 404(a) of Regulation S-K, and that he was not selected pursuant to any arrangement or understanding with any other person.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Board Expands to 11 Members from 10

The company said it increased the size of its Board of Directors from 10 to 11 members on February 1, 2024 and appointed Brian J. McNamara to the Board, effective February 1, 2024.

Source · Based on the filing body and exhibits

McNamara's Current Role and Background

The company said McNamara has been Chief Executive Officer of Haleon plc (formerly GSK ConsumerHealthcare) since May 2022, and previously led GSK's Consumer Healthcare business.

Source · Based on the filing body and exhibits

Committee Assignments and Independence Determination

The company said it appointed McNamara to the People and Compensation Committee and the Governance, Membership and Sustainability Committee, and that the Board determined he is an independent director under Nasdaq listing rules. According to the press release, 10 of the 11 directors, including McNamara, are deemed independent.

Source · Based on the filing body and exhibits

Compensation, Interests and Selection Process

The company said McNamara will receive the same compensation and indemnification as its other non-employee directors, that there are no transactions between him and the company reportable under Item 404(a) of Regulation S-K, and that he was not selected pursuant to any arrangement or understanding with any other person.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.